Literature DB >> 27095042

Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan.

Hsiao-Wen Kao1,2, Tung-Liang Lin1, Lee-Yung Shih1,3, Po Dunn1,3, Ming-Chung Kuo1,3, Yu-Shin Hung1, Jin-Hou Wu1, Tzung-Chih Tang1,3, Hung Chang1,3, Tseng-Tong Kuo3,4, Che-Wei Ou1, Po-Nan Wang5.   

Abstract

We retrospectively analyzed 87 patients with angioimmunoblastic T cell lymphoma (AITL) in Taiwan. The median age was 68 (range 18-89) years. Of these patients, 74 % was at an advanced stage. The most common extra-nodal site involved was bone marrow (36 %). Of these patients, 77 % were International Prognostic Index (IPI) >1 and 79 % had a prognostic index for peripheral T-cell lymphoma (PIT) >1. Of 75 patients who received systemic chemotherapy, the complete remission rate was 60 %, the relapse rate was 47 %, and the 2-year progression-free survival rate was 37.4 %. The 2-year overall survival (OS) rate for all patients was 51.9 %. By multivariate analysis, bone marrow involvement (P < 0.001) and ECOG >1 (P = 0.007) were independent adverse factors for OS. A simplified prognostic index efficiently stratified patients into the following three groups: 2-year OS rates 79.8 % (0 factor), 28.3 % (1 factor), and 10.2 % (2 factors) by using bone marrow involvement and ECOG >1 (P < 0.001). In conclusion, AITL patients were older and had poorer prognosis in Taiwan. Bone marrow involvement, EOCG >1, IPI >1 and PIT >1 had adverse impact on OS. The usefulness of this simplified prognostic index needs further validation.

Entities:  

Keywords:  Angioimmunoblastic T cell lymphoma; Chemotherapy; Outcome; Prognostic index; Stem cell transplantation

Mesh:

Substances:

Year:  2016        PMID: 27095042     DOI: 10.1007/s12185-016-2010-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.319


  19 in total

1.  Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan.

Authors:  Takashi Tokunaga; Kazuyuki Shimada; Kazuhito Yamamoto; Dai Chihara; Takuji Ichihashi; Rika Oshima; Mitsune Tanimoto; Toshihiro Iwasaki; Atsushi Isoda; Akira Sakai; Hikaru Kobayashi; Kunio Kitamura; Kosei Matsue; Masafumi Taniwaki; Sadahiro Tamashima; Yoshio Saburi; Taro Masunari; Tomoki Naoe; Shigeo Nakamura; Tomohiro Kinoshita
Journal:  Blood       Date:  2012-02-02       Impact factor: 22.113

Review 2.  CD30 expression in peripheral T-cell lymphomas.

Authors:  Elena Sabattini; Marco Pizzi; Valentina Tabanelli; Pamela Baldin; Carlo Sagramoso Sacchetti; Claudio Agostinelli; Pier Luigi Zinzani; Stefano A Pileri
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

3.  Brentuximab vedotin.

Authors:  Stephen M Ansell
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

4.  Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.

Authors:  Han-Nan Lin; Chun-Yu Liu; Ying-Chung Hong; Jih-Tung Pai; Ching-Fen Yang; Yuan-Bin Yu; Liang-Tsai Hsiao; Tzeon-Jye Chiou; Jin-Hwang Liu; Jyh-Pyng Gau; Cheng-Hwai Tzeng; Po-Min Chen
Journal:  Leuk Lymphoma       Date:  2010-11-05

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

Authors:  Nathalie Mourad; Nicolas Mounier; Josette Brière; Emmanuel Raffoux; Alain Delmer; Alfred Feller; Chris J L M Meijer; Jean-François Emile; Réda Bouabdallah; André Bosly; Jacques Diebold; Corinne Haioun; Bertrand Coiffier; Christian Gisselbrecht; Philippe Gaulard
Journal:  Blood       Date:  2008-02-21       Impact factor: 22.113

7.  Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Johannes Schetelig; Sebastian Fetscher; Albrecht Reichle; Wolfgang E Berdel; Yves Beguin; Salut Brunet; Dolores Caballero; Ignazio Majolino; Hans Hagberg; Hans E Johnsen; Eva Kimby; Emilio Montserrat; Douglas Stewart; Adrian Copplestone; Wolf Rösler; Jindra Pavel; Dorothea Kingreen; Wolfgang Siegert
Journal:  Haematologica       Date:  2003-11       Impact factor: 9.941

Review 8.  Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications.

Authors:  Kieron Dunleavy; Wyndham H Wilson; Elaine S Jaffe
Journal:  Curr Opin Hematol       Date:  2007-07       Impact factor: 3.284

9.  Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project.

Authors:  Massimo Federico; Thomas Rudiger; Monica Bellei; Bharat N Nathwani; Stefano Luminari; Bertrand Coiffier; Nancy L Harris; Elaine S Jaffe; Stefano A Pileri; Kerry J Savage; Dennis D Weisenburger; James O Armitage; Nicholas Mounier; Julie M Vose
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

10.  Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases.

Authors:  Kennosuke Karube; Ryosuke Aoki; Yuko Nomura; Kohei Yamamoto; Kay Shimizu; Shirou Yoshida; Hideki Komatani; Yasuo Sugita; Koichi Ohshima
Journal:  Pathol Int       Date:  2008-02       Impact factor: 2.534

View more
  2 in total

1.  Development of a Novel Clinical Prognostic Model for Patients With Angioimmunoblastic T-Cell Lymphoma.

Authors:  Chen Huang; Huichao Zhang; Yuhuan Gao; Lanping Diao; Lihong Liu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

2.  High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center.

Authors:  Jingrong Qian; Hongxue Meng; Bowen Lv; Jie Wang; Yingying Lu; Liju Su; Shu Zhao; Wenhui Li
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.